The Center for Immuno-Oncology established the Immune Assessment Laboratory to assist investigators at Dana-Farber Cancer Institute, its partners and external sites in establishing mechanistic and biomarker endpoints for clinical studies. With the recent success of immunotherapies through vaccines and checkpoint blockade targeted monoclonal antibodies, the goal of our Laboratory is to provide researchers with access to the latest innovations in immune monitoring in a quality-controlled setting.
The Lab offers technical support and scientific advice to investigators at Dana-Farber Cancer Institute and its partners who are interested in performing clinical studies related to cancer immunotherapies.
We provide data generation for clinical trials across multiple disease centers as well as the necessary expertise to design and develop assays related to cancer immunology biomarkers.
We are also involved in the collection of blood and solid tissue from patients participating in more than 50 clinical trials at DFCI as well as multiple external sites.
Our Lab is equipped with the latest technologies for the detection of soluble biomarkers, next generation sequencing, as well as determining cellular phenotypes.